Department 01
We design polymeric, dendritic and hybrid biomaterials for prevention, diagnosis, monitoring and therapy, connecting molecular design with laboratory and preclinical validation.
Development pipeline
The pipeline below translates the supplied programme overview into a clearer development map. A completed marker indicates that the project has reached that work package; it does not represent regulatory approval or a completed clinical programme.
| Projects | Synthesis, formulation & characterisation | In-vitro cytotoxicity | In-vitro cellular uptake | In-vivo studies | Clinical trials I & II |
|---|---|---|---|---|---|
| Nanohydrogels for cancer | |||||
| Ac-Dex nanoparticles for cancer | |||||
| Ac-Dex nanoparticles for bacterial infections | |||||
| Multifunctional dendrimers for cancer | |||||
| Dendritic vesosomes for cancer | |||||
| Injectable hydrogels for cancer |
Ongoing projects
Each project combines a material platform with a defined biological objective. The descriptions reflect the current scientific scope and the stages shown in the supplied pipeline.
Nanohydrogels are nanoscale, water-rich polymer networks designed to carry therapeutic agents and control their interaction with tumour tissue. This programme has progressed from formulation and physicochemical characterisation through in-vitro cytotoxicity and cellular-uptake studies to in-vivo evaluation.
Acetalated-dextran nanoparticles provide a biodegradable, stimulus-responsive carrier for the co-encapsulation and controlled release of anticancer compounds. The platform has reached formulation, cytotoxicity, cellular-uptake and in-vivo work packages.
This programme adapts the Ac-Dex platform to antimicrobial payloads, seeking stable formulations that can improve delivery at sites of infection. Synthesis, formulation and initial in-vitro cytotoxicity evaluation have been completed in the current pipeline.
Precisely branched dendrimers are being developed as multifunctional architectures able to combine therapeutic, targeting and imaging functions in one molecular platform. Current work covers synthesis, formulation, characterisation and in-vitro cytotoxicity.
Hierarchically self-assembled dendritic vesosomes create multi-compartment structures with potential for nanotheranostics and combination delivery. The programme has reached formulation, cytotoxicity and cellular-uptake evaluation.
Injectable hydrogels are being designed as local therapeutic depots that form or remain at the administration site, supporting sustained and spatially controlled delivery. The current programme is at synthesis, formulation and characterisation stage.
